Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Prostate Cancer

Free Subscription Articles published in Br J Cancer Retrieve available abstracts of 100 articles: HTML format

Single Articles

October 2024
1. RAHMAN R, Rahaman MH, Hanson AR, Choo N, et al
   Author Correction: CDK9 inhibition constrains multiple oncogenic transcriptional and epigenetic pathways in prostate cancer.
   Br J Cancer. 2024 Oct 24. doi: 10.1038/s41416-024-02862.
   PubMed    
   
   
   
2. SHEN M, Garcia-Marques F, Muruganantham A, Liu S, et al
   Identification of a 5-gene signature panel for the prediction of prostate cancer progression.
   Br J Cancer. 2024 Oct 14. doi: 10.1038/s41416-024-02854.
   PubMed     Abstract available
   
   
   September 2024
3. CHOW ST, Fan J, Zhang X, Wang Y, et al
   Nuclear receptor TLX functions to promote cancer stemness and EMT in prostate cancer via its direct transactivation of CD44 and stem cell-regulatory transcription factors.
   Br J Cancer. 2024 Sep 26. doi: 10.1038/s41416-024-02843.
   PubMed     Abstract available
   
   
   
4. WANG T, Wang X, Ding G, Liu H, et al
   Efficacy and safety evaluation of androgen deprivation therapy-based combinations for metastatic castration-sensitive prostate cancer: a systematic review and network meta-analysis.
   Br J Cancer. 2024 Sep 2. doi: 10.1038/s41416-024-02823.
   PubMed     Abstract available
   
   
   August 2024
5. NTURUBIKA BD, Guardia CM, Gershlick DC, Logan JM, et al
   Altered expression of vesicular trafficking machinery in prostate cancer affects lysosomal dynamics and provides insight into the underlying biology and disease progression.
   Br J Cancer. 2024 Aug 31. doi: 10.1038/s41416-024-02829.
   PubMed     Abstract available
   
   
   
6. RAHMAN R, Rahaman MH, Hanson AR, Choo N, et al
   CDK9 inhibition inhibits multiple oncogenic transcriptional and epigenetic pathways in prostate cancer.
   Br J Cancer. 2024 Aug 8. doi: 10.1038/s41416-024-02810.
   PubMed     Abstract available
   
   
   July 2024
7. LIN BB, Huang Q, Yan B, Liu M, et al
   An 18-gene signature of recurrence-associated endothelial cells predicts tumor progression and castration resistance in prostate cancer.
   Br J Cancer. 2024 Jul 12. doi: 10.1038/s41416-024-02761.
   PubMed     Abstract available
   
   
   
8. PUJANA-VAQUERIZO M, Bozal-Basterra L, Carracedo A
   Metabolic adaptations in prostate cancer.
   Br J Cancer. 2024 Jul 5. doi: 10.1038/s41416-024-02762.
   PubMed     Abstract available
   
   
   
9. CYLL K, Skaaheim Haug E, Pradhan M, Vlatkovic L, et al
   DNA ploidy and PTEN as biomarkers for predicting aggressive disease in prostate cancer patients under active surveillance.
   Br J Cancer. 2024 Jul 3. doi: 10.1038/s41416-024-02780.
   PubMed     Abstract available
   
   
   June 2024
10. ARMAKOLAS A, Alevizopoulos N, Stathaki M, Petraki C, et al
    Anti-PEc: Development of a novel monoclonal antibody against prostate cancer.
    Br J Cancer. 2024 Jun 20. doi: 10.1038/s41416-024-02713.
    PubMed     Abstract available
    
    
    March 2024
11. ZHANG Y, Stopsack KH, Wu K, Song M, et al
    Multivitamin use after diagnosis and prostate cancer survival among men with nonmetastatic prostate cancer.
    Br J Cancer. 2024 Mar 15. doi: 10.1038/s41416-024-02651.
    PubMed     Abstract available
    
    
    
12. GNANAPRAGASAM V
    Shifting the paradigm in the management of early prostate cancer.
    Br J Cancer. 2024 Mar 6. doi: 10.1038/s41416-024-02641.
    PubMed     Abstract available
    
    
    February 2024
13. EBERLEIN C, Williamson SC, Hopcroft L, Ros S, et al
    Capivasertib combines with docetaxel to enhance anti-tumour activity through inhibition of AKT-mediated survival mechanisms in prostate cancer.
    Br J Cancer. 2024 Feb 23. doi: 10.1038/s41416-024-02614.
    PubMed     Abstract available
    
    
    
14. LIU Q, Zhang Y, Vaselkiv JB, Mucci LA, et al
    A prospective study of birth weight and prostate cancer risk and mortality in the Health Professionals Follow-up Study.
    Br J Cancer. 2024 Feb 22. doi: 10.1038/s41416-024-02593.
    PubMed     Abstract available
    
    
    
15. CONSTANTIN TA, Varela-Carver A, Greenland KK, de Almeida GS, et al
    Correction: The CDK7 inhibitor CT7001 (Samuraciclib) targets proliferation pathways to inhibit advanced prostate cancer.
    Br J Cancer. 2024 Feb 14. doi: 10.1038/s41416-024-02606.
    PubMed    
    
    
    
16. O'MALLEY DE, Raspin K, Melton PE, Burdon KP, et al
    Acquired copy number variation in prostate tumours: a review of common somatic copy number alterations, how they are formed and their clinical utility.
    Br J Cancer. 2024;130:347-357.
    PubMed     Abstract available
    
    
    January 2024
17. MAH CY, Nguyen ADT, Niijima T, Helm M, et al
    Peroxisomal beta-oxidation enzyme, DECR2, regulates lipid metabolism and promotes treatment resistance in advanced prostate cancer.
    Br J Cancer. 2024 Jan 12. doi: 10.1038/s41416-023-02557.
    PubMed     Abstract available
    
    
    December 2023
18. FRITZ J, Jochems SHJ, Bjorge T, Wood AM, et al
    Body mass index, triglyceride-glucose index, and prostate cancer death: a mediation analysis in eight European cohorts.
    Br J Cancer. 2023 Dec 12. doi: 10.1038/s41416-023-02526.
    PubMed     Abstract available
    
    
    November 2023
19. ZHAO JL, Antonarakis ES, Cheng HH, George DJ, et al
    Phase 1b study of enzalutamide plus CC-115, a dual mTORC1/2 and DNA-PK inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC).
    Br J Cancer. 2023 Nov 18. doi: 10.1038/s41416-023-02487.
    PubMed     Abstract available
    
    
    
20. SHEN J, Chowdhury S, Agarwal N, Karsh LI, et al
    Apalutamide efficacy, safety and wellbeing in older patients with advanced prostate cancer from Phase 3 randomised clinical studies TITAN and SPARTAN.
    Br J Cancer. 2023 Nov 11. doi: 10.1038/s41416-023-02492.
    PubMed     Abstract available
    
    
    
21. AHMAD AS, Offman J, Delon C, North BV, et al
    Years of life lost due to cancer in the United Kingdom from 1988 to 2017.
    Br J Cancer. 2023;129:1558-1568.
    PubMed     Abstract available
    
    
    
22. CAMERON JM, Sala A, Antoniou G, Brennan PM, et al
    A spectroscopic liquid biopsy for the earlier detection of multiple cancer types.
    Br J Cancer. 2023;129:1658-1666.
    PubMed     Abstract available
    
    
    
23. SHEN M, Liu S, Toland A, Hsu EC, et al
    ACAA2 is a novel molecular indicator for cancers with neuroendocrine phenotype.
    Br J Cancer. 2023;129:1818-1828.
    PubMed     Abstract available
    
    
    October 2023
24. FENG X, Zhang Y, Vaselkiv JB, Li R, et al
    Modifiable risk factors for subsequent lethal prostate cancer among men with an initially negative prostate biopsy.
    Br J Cancer. 2023 Oct 28. doi: 10.1038/s41416-023-02472.
    PubMed     Abstract available
    
    
    
25. TURPIN A, Delliaux C, Parent P, Chevalier H, et al
    Fascin-1 expression is associated with neuroendocrine prostate cancer and directly suppressed by androgen receptor.
    Br J Cancer. 2023 Oct 24. doi: 10.1038/s41416-023-02449.
    PubMed     Abstract available
    
    
    
26. GULLIVER C, Huss S, Semjonow A, Baillie GS, et al
    Loss of PDE4D7 expression promotes androgen independence, neuroendocrine differentiation and alterations in DNA repair: implications for therapeutic strategies.
    Br J Cancer. 2023;129:1462-1476.
    PubMed     Abstract available
    
    
    September 2023
27. HOU Y, Jiang KW, Wang LL, Zhi R, et al
    Biopsy-free AI-aided precision MRI assessment in prediction of prostate cancer biochemical recurrence.
    Br J Cancer. 2023 Sep 27. doi: 10.1038/s41416-023-02441.
    PubMed     Abstract available
    
    
    
28. HINNEH JA, Gillis JL, Mah CY, Irani S, et al
    Targeting hyaluronan-mediated motility receptor (HMMR) enhances response to androgen receptor signalling inhibitors in prostate cancer.
    Br J Cancer. 2023 Sep 6. doi: 10.1038/s41416-023-02406.
    PubMed     Abstract available
    
    
    August 2023
29. MACAULAY VM, Lord S, Hussain S, Maroto JP, et al
    A Phase Ib/II study of IGF-neutralising antibody xentuzumab with enzalutamide in metastatic castration-resistant prostate cancer.
    Br J Cancer. 2023 Aug 3. doi: 10.1038/s41416-023-02380.
    PubMed     Abstract available
    
    
    July 2023
30. HIRATA H, Hinoda Y, Shahryari V, Deng G, et al
    Editorial Expression of Concern: Genistein downregulates onco-miR-1260b and upregulates sFRP1 and Smad4 via demethylation and histone modification in prostate cancer cells.
    Br J Cancer. 2023 Jul 28. doi: 10.1038/s41416-023-02365.
    PubMed    
    
    
    
31. WANG A, Wan P, Hebert JR, Le Marchand L, et al
    Atopic allergic conditions and prostate cancer risk and survival in the Multiethnic Cohort study.
    Br J Cancer. 2023 Jul 24. doi: 10.1038/s41416-023-02364.
    PubMed     Abstract available
    
    
    
32. LI X, Chen Y, Bai L, Zhao R, et al
    Nicardipine is a putative EED inhibitor and has high selectivity and potency against chemoresistant prostate cancer in preclinical models.
    Br J Cancer. 2023 Jul 20. doi: 10.1038/s41416-023-02359.
    PubMed     Abstract available
    
    
    
33. CONTEDUCA V, Brighi N, Schepisi G, De Giorgi U, et al
    Immunogenomic profiles associated with response to life-prolonging agents in prostate cancer.
    Br J Cancer. 2023 Jul 13. doi: 10.1038/s41416-023-02354.
    PubMed     Abstract available
    
    
    
34. WATLING CZ, Kelly RK, Dunneram Y, Knuppel A, et al
    Associations of intakes of total protein, protein from dairy sources, and dietary calcium with risks of colorectal, breast, and prostate cancer: a prospective analysis in UK Biobank.
    Br J Cancer. 2023 Jul 5. doi: 10.1038/s41416-023-02339.
    PubMed     Abstract available
    
    
    May 2023
35. LANGLAIS CS, Graff RE, Van Blarigan EL, Neuhaus JM, et al
    Post-diagnostic health behaviour scores and risk of prostate cancer progression and mortality.
    Br J Cancer. 2023 May 22. doi: 10.1038/s41416-023-02283.
    PubMed     Abstract available
    
    
    
36. SALMON C, Quesnel-Vallee A, Barnett TA, Benedetti A, et al
    Neighbourhood social deprivation and risk of prostate cancer.
    Br J Cancer. 2023 May 15. doi: 10.1038/s41416-023-02299.
    PubMed     Abstract available
    
    
    April 2023
37. LAUTERT-DUTRA W, Dos Reis RB, Squire JA
    Precision medicine for prostate cancer-improved outcome prediction for low-intermediate risk disease using a six-gene copy number alteration classifier.
    Br J Cancer. 2023 Apr 29. doi: 10.1038/s41416-023-02289.
    PubMed     Abstract available
    
    
    
38. CHAN JSK, Satti DI, Lee YHA, Hui JMH, et al
    Temporal trends in cardiovascular burden among patients with prostate cancer receiving androgen deprivation therapy: a population-based cohort study.
    Br J Cancer. 2023 Apr 19. doi: 10.1038/s41416-023-02271.
    PubMed     Abstract available
    
    
    
39. CONSTANTIN TA, Varela-Carver A, Greenland KK, de Almeida GS, et al
    The CDK7 inhibitor CT7001 (Samuraciclib) targets proliferation pathways to inhibit advanced prostate cancer.
    Br J Cancer. 2023 Apr 19. doi: 10.1038/s41416-023-02252.
    PubMed     Abstract available
    
    
    
40. EBRAHIMIZADEH W, Guerard KP, Rouzbeh S, Scarlata E, et al
    A DNA copy number alteration classifier as a prognostic tool for prostate cancer patients.
    Br J Cancer. 2023 Apr 10. doi: 10.1038/s41416-023-02236.
    PubMed     Abstract available
    
    
    March 2023
41. TIBBO AJ, Hartley A, Vasan R, Shaw R, et al
    MBTPS2 acts as a regulator of lipogenesis and cholesterol synthesis through SREBP signalling in prostate cancer.
    Br J Cancer. 2023 Mar 29. doi: 10.1038/s41416-023-02237.
    PubMed     Abstract available
    
    
    
42. ZHOU Q, Ou Y, Dai X, Chen X, et al
    Correction to: Prevalence of tumour-infiltrating CD103(+) cells identifies therapeutic-sensitive prostate cancer with poor clinical outcome.
    Br J Cancer. 2023 Mar 20. doi: 10.1038/s41416-023-02211.
    PubMed    
    
    
    February 2023
43. ZHOU Q, Ou Y, Dai X, Chen X, et al
    Prevalence of tumour-infiltrating CD103(+) cells identifies therapeutic-sensitive prostate cancer with poor clinical outcome.
    Br J Cancer. 2023 Feb 9. doi: 10.1038/s41416-023-02183.
    PubMed     Abstract available
    
    
    January 2023
44. TAO W, Luo ZH, He YD, Wang BY, et al
    Plasma extracellular vesicle circRNA signature and resistance to abiraterone in metastatic castration-resistant prostate cancer.
    Br J Cancer. 2023 Jan 26. doi: 10.1038/s41416-023-02147.
    PubMed     Abstract available
    
    
    
45. LI J, Liu N, Zhou H, Xian P, et al
    Immunoproteasome inhibition prevents progression of castration-resistant prostate cancer.
    Br J Cancer. 2023 Jan 21. doi: 10.1038/s41416-022-02129.
    PubMed     Abstract available
    
    
    
46. BAO J, Hou Y, Qin L, Zhi R, et al
    High-throughput precision MRI assessment with integrated stack-ensemble deep learning can enhance the preoperative prediction of prostate cancer Gleason grade.
    Br J Cancer. 2023 Jan 17. doi: 10.1038/s41416-022-02134.
    PubMed     Abstract available
    
    
    
47. LIN J, Nousome D, Jiang J, Chesnut GT, et al
    Five-year survival of patients with late-stage prostate cancer: comparison of the Military Health System and the U.S. general population.
    Br J Cancer. 2023 Jan 6. doi: 10.1038/s41416-022-02136.
    PubMed     Abstract available
    
    
    
48. YU R, Jiang KW, Bao J, Hou Y, et al
    PI-RADS(AI): introducing a new human-in-the-loop AI model for prostate cancer diagnosis based on MRI.
    Br J Cancer. 2023 Jan 4. doi: 10.1038/s41416-022-02137.
    PubMed     Abstract available
    
    
    December 2022
49. CARDOSO M, Maia S, Brandao A, Sahasrabudhe R, et al
    Exome sequencing of affected duos and trios uncovers PRUNE2 as a novel prostate cancer predisposition gene.
    Br J Cancer. 2022 Dec 23. doi: 10.1038/s41416-022-02125.
    PubMed     Abstract available
    
    
    
50. BLANC C, Moktefi A, Jolly A, de la Grange P, et al
    The Neuropilin-1/PKC axis promotes neuroendocrine differentiation and drug resistance of prostate cancer.
    Br J Cancer. 2022 Dec 22. doi: 10.1038/s41416-022-02114.
    PubMed     Abstract available
    
    
    
51. GREEN HD, Merriel SWD, Oram RA, Ruth KS, et al
    Response to: Genetic risk scores may compound rather than solve the issue of prostate cancer overdiagnosis (BJC-LT3342090).
    Br J Cancer. 2022 Dec 19. doi: 10.1038/s41416-022-02081.
    PubMed    
    
    
    
52. LIN E, Garmo H, Hagstrom E, Van Hemelrijck M, et al
    Association between atherogenic lipids and GnRH agonists for prostate cancer in men with T2DM: a nationwide, population-based cohort study in Sweden.
    Br J Cancer. 2022 Dec 15. doi: 10.1038/s41416-022-02091.
    PubMed     Abstract available
    
    
    
53. HARTLEY A, Ahmad I
    The role of PPARgamma in prostate cancer development and progression.
    Br J Cancer. 2022 Dec 12. doi: 10.1038/s41416-022-02096.
    PubMed     Abstract available
    
    
    
54. PEDERZOLI F, Raffo M, Pakula H, Ravera F, et al
    "Stromal cells in prostate cancer pathobiology: friends or foes?".
    Br J Cancer. 2022 Dec 8. doi: 10.1038/s41416-022-02085.
    PubMed     Abstract available
    
    
    November 2022
55. HORTON RH, Dunlop MG, Houlston RS, Lucassen A, et al
    Genetic risk scores may compound rather than solve the issue of prostate cancer overdiagnosis.
    Br J Cancer. 2022 Nov 28. doi: 10.1038/s41416-022-02080.
    PubMed    
    
    
    
56. ROULEAU M, Nguyen Van Long F, Turcotte V, Caron P, et al
    Extensive metabolic consequences of human glycosyltransferase gene knockouts in prostate cancer.
    Br J Cancer. 2022 Nov 8. pii: 10.1038/s41416-022-02040.
    PubMed     Abstract available
    
    
    
57. EGGER S, Smith DP, Patel MI, Kimlin MG, et al
    Cutaneous melanoma, prostate-specific antigen testing and the subsequent risk of prostate cancer diagnosis: a prospective analysis of the 45 and Up Study.
    Br J Cancer. 2022 Nov 1. pii: 10.1038/s41416-022-02027.
    PubMed     Abstract available
    
    
    October 2022
58. LAN T, Park Y, Colditz GA, Liu J, et al
    Adolescent dietary patterns in relation to later prostate cancer risk and mortality in the NIH-AARP Diet and Health Study.
    Br J Cancer. 2022 Oct 31. pii: 10.1038/s41416-022-02035.
    PubMed     Abstract available
    
    
    
59. BUTLER EN, Zhou CK, Curry M, McMenamin U, et al
    Testosterone therapy and cancer risks among men in the SEER-Medicare linked database.
    Br J Cancer. 2022 Oct 28. pii: 10.1038/s41416-022-02019.
    PubMed     Abstract available
    
    
    
60. RODRIGUEZ-VIDA A, Maroto P, Font A, Martin C, et al
    Safety and efficacy of avelumab plus carboplatin in patients with metastatic castration-resistant prostate cancer in an open-label Phase Ib study.
    Br J Cancer. 2022 Oct 26. pii: 10.1038/s41416-022-01991.
    PubMed     Abstract available
    
    
    
61. CROWLEY F, Mihalopoulos M, Gaglani S, Tewari AK, et al
    Prostate cancer in transgender women: considerations for screening, diagnosis and management.
    Br J Cancer. 2022 Oct 19. pii: 10.1038/s41416-022-01989.
    PubMed     Abstract available
    
    
    
62. GLUD EN, Rasmussen M, Zhang Y, Mandrup OA, et al
    Identification of a high-risk immunogenic prostate cancer patient subset as candidates for T-cell engager immunotherapy and the introduction of a novel albumin-fused anti-CD3 x anti-PSMA bispecific design.
    Br J Cancer. 2022 Oct 15. pii: 10.1038/s41416-022-01994.
    PubMed     Abstract available
    
    
    August 2022
63. GRAFF RE, Langlais CS, Van Blarigan EL, Pernar CH, et al
    Post-diagnostic health behaviour scores in relation to fatal prostate cancer.
    Br J Cancer. 2022 Aug 26. pii: 10.1038/s41416-022-01948.
    PubMed     Abstract available
    
    
    
64. KIMURA H, Mizuno K, Shiota M, Narita S, et al
    Prognostic significance of pathogenic variants in BRCA1, BRCA2, ATM and PALB2 genes in men undergoing hormonal therapy for advanced prostate cancer.
    Br J Cancer. 2022 Aug 19. pii: 10.1038/s41416-022-01915.
    PubMed     Abstract available
    
    
    
65. GREEN HD, Merriel SWD, Oram RA, Ruth KS, et al
    Applying a genetic risk score for prostate cancer to men with lower urinary tract symptoms in primary care to predict prostate cancer diagnosis: a cohort study in the UK Biobank.
    Br J Cancer. 2022 Aug 18. pii: 10.1038/s41416-022-01918.
    PubMed     Abstract available
    
    
    July 2022
66. SACHDEVA A, Hart CA, Kim K, Tawadros T, et al
    Non-canonical EphA2 activation underpins PTEN-mediated metastatic migration and poor clinical outcome in prostate cancer.
    Br J Cancer. 2022 Jul 22. pii: 10.1038/s41416-022-01914.
    PubMed     Abstract available
    
    
    June 2022
67. TRUJILLO B, Wu A, Wetterskog D, Attard G, et al
    Blood-based liquid biopsies for prostate cancer: clinical opportunities and challenges.
    Br J Cancer. 2022 Jun 17. pii: 10.1038/s41416-022-01881.
    PubMed     Abstract available
    
    
    May 2022
68. NAIR-SHALLIKER V, Bang A, Egger S, Yu XQ, et al
    Family history, obesity, urological factors and diabetic medications and their associations with risk of prostate cancer diagnosis in a large prospective study.
    Br J Cancer. 2022 May 24. pii: 10.1038/s41416-022-01827.
    PubMed     Abstract available
    
    
    
69. SALMINEN JK, Mehtola A, Talala K, Taari K, et al
    Anti-epileptic drugs and prostate cancer-specific mortality compared to non-users of anti-epileptic drugs in the Finnish Randomized Study of Screening for Prostate Cancer.
    Br J Cancer. 2022 May 3. pii: 10.1038/s41416-022-01817.
    PubMed     Abstract available
    
    
    April 2022
70. OWARI T, Tanaka N, Nakai Y, Miyake M, et al
    5-Aminolevulinic acid overcomes hypoxia-induced radiation resistance by enhancing mitochondrial reactive oxygen species production in prostate cancer cells.
    Br J Cancer. 2022 Apr 1. pii: 10.1038/s41416-022-01789.
    PubMed     Abstract available
    
    
    
71. RASMUSSEN M, Fredsoe J, Tin AL, Vickers AJ, et al
    Independent validation of a pre-specified four-kallikrein marker model for prediction of adverse pathology and biochemical recurrence.
    Br J Cancer. 2022;126:1004-1009.
    PubMed     Abstract available
    
    
    March 2022
72. SALBERG UB, Skingen VE, Fjeldbo CS, Hompland T, et al
    A prognostic hypoxia gene signature with low heterogeneity within the dominant tumour lesion in prostate cancer patients.
    Br J Cancer. 2022 Mar 24. pii: 10.1038/s41416-022-01782.
    PubMed     Abstract available
    
    
    February 2022
73. SLOOTBEEK PHJ, Kloots ISH, Smits M, van Oort IM, et al
    Correction to: Impact of molecular tumour board discussion on targeted therapy allocation in advanced prostate cancer.
    Br J Cancer. 2022 Feb 24. pii: 10.1038/s41416-022-01765.
    PubMed    
    
    
    January 2022
74. RANA S, Valbuena GN, Curry E, Bevan CL, et al
    MicroRNAs as biomarkers for prostate cancer prognosis: a systematic review and a systematic reanalysis of public data.
    Br J Cancer. 2022 Jan 12. pii: 10.1038/s41416-021-01677.
    PubMed     Abstract available
    
    
    December 2021
75. NYBERG T, Tischkowitz M, Antoniou AC
    BRCA1 and BRCA2 pathogenic variants and prostate cancer risk: systematic review and meta-analysis.
    Br J Cancer. 2021 Dec 28. pii: 10.1038/s41416-021-01675.
    PubMed     Abstract available
    
    
    
76. MCHUGH J, Saunders EJ, Dadaev T, McGrowder E, et al
    Prostate cancer risk in men of differing genetic ancestry and approaches to disease screening and management in these groups.
    Br J Cancer. 2021 Dec 18. pii: 10.1038/s41416-021-01669.
    PubMed     Abstract available
    
    
    
77. SLOOTBEEK PHJ, Kloots ISH, Smits M, van Oort IM, et al
    Impact of molecular tumour board discussion on targeted therapy allocation in advanced prostate cancer.
    Br J Cancer. 2021 Dec 15. pii: 10.1038/s41416-021-01663.
    PubMed     Abstract available
    
    
    November 2021
78. SRIVASTAVA SK, Khan MA, Anand S, Zubair H, et al
    MYB interacts with androgen receptor, sustains its ligand-independent activation and promotes castration resistance in prostate cancer.
    Br J Cancer. 2021 Nov 26. pii: 10.1038/s41416-021-01641.
    PubMed     Abstract available
    
    
    
79. WEN YC, Liu CL, Yeh HL, Chen WH, et al
    PCK1 regulates neuroendocrine differentiation in a positive feedback loop of LIF/ZBTB46 signalling in castration-resistant prostate cancer.
    Br J Cancer. 2021 Nov 24. pii: 10.1038/s41416-021-01631.
    PubMed     Abstract available
    
    
    
80. RAMIREZ-GARRASTACHO M, Berge V, Line A, Llorente A, et al
    Potential of miRNAs in urinary extracellular vesicles for management of active surveillance in prostate cancer patients.
    Br J Cancer. 2021 Nov 22. pii: 10.1038/s41416-021-01598.
    PubMed     Abstract available
    
    
    
81. RAMIREZ-GARRASTACHO M, Bajo-Santos C, Line A, Martens-Uzunova ES, et al
    Extracellular vesicles as a source of prostate cancer biomarkers in liquid biopsies: a decade of research.
    Br J Cancer. 2021 Nov 22. pii: 10.1038/s41416-021-01610.
    PubMed     Abstract available
    
    
    
82. HATANO K, Yoneyama T, Hatakeyama S, Tomiyama E, et al
    Simultaneous analysis of serum alpha2,3-linked sialylation and core-type fucosylation of prostate-specific antigen for the detection of high-grade prostate cancer.
    Br J Cancer. 2021 Nov 20. pii: 10.1038/s41416-021-01637.
    PubMed     Abstract available
    
    
    
83. NA R, Wei J, Sample CJ, Gielzak M, et al
    The HOXB13 variant X285K is associated with clinical significance and early age at diagnosis in African American prostate cancer patients.
    Br J Cancer. 2021 Nov 19. pii: 10.1038/s41416-021-01622.
    PubMed     Abstract available
    
    
    September 2021
84. YU H, Xie M, Meng Z, Lo CY, et al
    Endolysosomal ion channel MCOLN2 (Mucolipin-2) promotes prostate cancer progression via IL-1beta/NF-kappaB pathway.
    Br J Cancer. 2021 Sep 21. pii: 10.1038/s41416-021-01537.
    PubMed     Abstract available
    
    
    
85. KAKOURATOS C, Kalamida D, Lamprou I, Xanthopoulou E, et al
    Apalutamide radio-sensitisation of prostate cancer.
    Br J Cancer. 2021 Sep 1. pii: 10.1038/s41416-021-01528.
    PubMed     Abstract available
    
    
    
86. LIU Z, Thong MSY, Doege D, Koch-Gallenkamp L, et al
    Prevalence of benefit finding and posttraumatic growth in long-term cancer survivors: results from a multi-regional population-based survey in Germany.
    Br J Cancer. 2021;125:877-883.
    PubMed     Abstract available
    
    
    July 2021
87. DE GIORGI U, Sansovini M, Severi S, Nicolini S, et al
    Circulating androgen receptor gene amplification and resistance to (177)Lu-PSMA-617 in metastatic castration-resistant prostate cancer: results of a Phase 2 trial.
    Br J Cancer. 2021 Jul 31. pii: 10.1038/s41416-021-01508.
    PubMed     Abstract available
    
    
    
88. ZHAO Z, Zhao S
    Reply to Comment on "miR-199b-5p-DDR1-ERK signalling axis suppresses prostate cancer metastasis via inhibiting epithelial-mesenchymal transition".
    Br J Cancer. 2021 Jul 20. pii: 10.1038/s41416-021-01493.
    PubMed    
    
    
    
89. AHMAD F, Cherukuri MK, Choyke PL
    Metabolic reprogramming in prostate cancer.
    Br J Cancer. 2021 Jul 14. pii: 10.1038/s41416-021-01435.
    PubMed     Abstract available
    
    
    
90. SUI Y, Hu W, Zhang W, Li D, et al
    Insights into homeobox B9: a propeller for metastasis in dormant prostate cancer progenitor cells.
    Br J Cancer. 2021 Jul 10. pii: 10.1038/s41416-021-01482.
    PubMed     Abstract available
    
    
    June 2021
91. SJOBERG HT, Philippou Y, Magnussen AL, Tullis IDC, et al
    Tumour irradiation combined with vascular-targeted photodynamic therapy enhances antitumour effects in pre-clinical prostate cancer.
    Br J Cancer. 2021 Jun 21. pii: 10.1038/s41416-021-01450.
    PubMed     Abstract available
    
    
    
92. LAN T, Park Y, Colditz GA, Liu J, et al
    Adolescent animal product intake in relation to later prostate cancer risk and mortality in the NIH-AARP Diet and Health Study.
    Br J Cancer. 2021 Jun 16. pii: 10.1038/s41416-021-01463.
    PubMed     Abstract available
    
    
    
93. CHEN F, Han Y, Kang Y
    Bone marrow niches in the regulation of bone metastasis.
    Br J Cancer. 2021;124:1912-1920.
    PubMed     Abstract available
    
    
    May 2021
94. CRISTOBAL I, Santos A, Rubio J, Rojo F, et al
    Comment on "miR-199b-5p-DDR1-ERK signalling axis suppresses prostate cancer metastasis via inhibiting epithelial-mesenchymal transition".
    Br J Cancer. 2021 May 19. pii: 10.1038/s41416-021-01433.
    PubMed    
    
    
    
95. WOKOLORCZYK D, Kluzniak W, Stempa K, Rusak B, et al
    PALB2 mutations and prostate cancer risk and survival.
    Br J Cancer. 2021 May 18. pii: 10.1038/s41416-021-01410.
    PubMed     Abstract available
    
    
    
96. FILON M, Gawdzik J, Truong A, Allen G, et al
    Tandem histone methyltransferase upregulation defines a unique aggressive prostate cancer phenotype.
    Br J Cancer. 2021 May 11. pii: 10.1038/s41416-021-01398.
    PubMed     Abstract available
    
    
    
97. AMADOU A, Freisling H, Jenab M, Tsilidis KK, et al
    Prevalent diabetes and risk of total, colorectal, prostate and breast cancers in an ageing population: meta-analysis of individual participant data from cohorts of the CHANCES consortium.
    Br J Cancer. 2021;124:1882-1890.
    PubMed     Abstract available
    
    
    April 2021
98. EMOND JP, Lacombe L, Caron P, Turcotte V, et al
    Urinary oestrogen steroidome as an indicator of the risk of localised prostate cancer progression.
    Br J Cancer. 2021 Apr 7. pii: 10.1038/s41416-021-01376.
    PubMed     Abstract available
    
    
    February 2021
99. BARCLAY ME, Abel GA, Greenberg DC, Rous B, et al
    Socio-demographic variation in stage at diagnosis of breast, bladder, colon, endometrial, lung, melanoma, prostate, rectal, renal and ovarian cancer in England and its population impact.
    Br J Cancer. 2021 Feb 9. pii: 10.1038/s41416-021-01279.
    PubMed     Abstract available
    
    
    December 2020
100. AMERATUNGA M, Brana I, Bono P, Postel-Vinay S, et al
     First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours.
     Br J Cancer. 2020;123:1730-1736.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.